TGFBR2 mutation predicts resistance to immune checkpoint inhibitors in patients with non-small cell lung cancer

BACKGROUND: Resistance or even hyper-progression to immune checkpoint inhibitors (ICIs) manifesting as accelerated disease progression or death has impeded the clinical use of ICIs. The transforming growth factor beta (TGFβ) receptor pathway has been identified in contributing to immune dysfunction,...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Teng, Wang, Han, Xu, Jiachen, Li, Chengcheng, Zhang, Yudong, Wang, Guoqiang, Liu, Yutao, Cai, Shangli, Fang, Wenfeng, Li, Junling, Wang, Zhijie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Immunotherapy for Lung Cancer: Progress, Opportunities and Challenges
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8366138/
https://www.ncbi.nlm.nih.gov/pubmed/34408796
http://dx.doi.org/10.1177/17588359211038477

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8366138/
https://www.ncbi.nlm.nih.gov/pubmed/34408796
http://dx.doi.org/10.1177/17588359211038477

Ejemplares similares